Pancreatic Cancer Research

ResearcherUniversity of TübingenActive in the last 2 years

Bence Sipos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7311-3343; OpenAlex author ID A5023421590, A5087624997, A5132649557. Sources: OpenAlex.

Their work

Papers
30 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
117
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 3 papers · 2016: 7 papers · 2017: 4 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 30

  1. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  2. Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag108↗
  3. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  4. Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. Co-author DOI 10.2967/jnumed.120.256776↗
  5. Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040725↗
  6. CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation. Co-author DOI 10.3390/cancers13102462↗
  7. Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subt… Co-author DOI 10.1200/po.18.00005↗
  8. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2017.02.005↗
  9. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.003↗
  10. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-310049↗
  11. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  12. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. Co-author DOI 10.1016/j.ajpath.2016.07.025↗
  13. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Co-author DOI 10.1053/j.gastro.2016.08.040↗
  14. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of M… Co-author DOI 10.1074/mcp.m115.054585↗
  15. miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. Co-author DOI 10.1080/2162402x.2016.1160181↗
  16. PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulator… Co-author DOI 10.1158/0008-5472.can-15-0216↗
  17. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.12455↗
  18. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.9402↗
  19. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  20. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Co-author DOI 10.1080/2162402x.2014.1000083↗
  21. A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0122946↗
  22. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.417↗
  23. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Co-author DOI 10.1093/carcin/bgt394↗
  24. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  25. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗
  26. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Co-author DOI 10.1136/gutjnl-2012-302577↗
  27. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.26502↗
  28. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Co-author DOI 10.1016/j.ccr.2011.03.009↗
  29. Early requirement of Rac1 in a mouse model of pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.04.043↗
  30. Prognostic significance of erythropoietin in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0023151↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Iréne Esposito · 5 shared papers, 2014–2026 · strength 0.55
  2. Jens Thomas Siveke · 7 shared papers, 2011–2026 · strength 0.54
  3. Roland Michael Schmid · 7 shared papers, 2011–2026 · strength 0.53
  4. Irina Heid · 5 shared papers, 2011–2026 · strength 0.45
  5. Stephan A. Hahn · 5 shared papers, 2012–2026 · strength 0.43
  6. Marija Trajkovic‐Arsic · 4 shared papers, 2015–2026 · strength 0.43
  7. Rickmer Braren · 4 shared papers, 2015–2026 · strength 0.42
  8. Matthias Wirth · 4 shared papers, 2015–2026 · strength 0.42
  9. Elisabeth Heßmann · 4 shared papers, 2015–2026 · strength 0.42
  10. Pawel Karol Mazur · 4 shared papers, 2011–2026 · strength 0.40
  11. Thomas Mathias Gress · 6 shared papers, 2013–2021 · strength 0.39
  12. Stephano S. Mello · 3 shared papers, 2015–2026 · strength 0.37
  13. Mert Erkan · 3 shared papers, 2015–2026 · strength 0.37
  14. Julien Sage · 3 shared papers, 2015–2026 · strength 0.37
  15. Alexander Herner · 3 shared papers, 2015–2026 · strength 0.37
  16. Jorg H. Kleeff · 3 shared papers, 2015–2026 · strength 0.37
  17. Laura D Attardi · 3 shared papers, 2015–2026 · strength 0.37
  18. Simone Hausmann · 3 shared papers, 2015–2026 · strength 0.37
  19. Volker Ellenrieder · 3 shared papers, 2015–2026 · strength 0.37
  20. Tyler Jacks · 3 shared papers, 2015–2026 · strength 0.37
  21. Uwe M. Martens · 2 shared papers, 2018–2026 · strength 0.36
  22. Stephanie Berger · 2 shared papers, 2018–2026 · strength 0.36
  23. Malte Buchholz · 6 shared papers, 2012–2021 · strength 0.34
  24. Heidi Griesmann · 4 shared papers, 2013–2021 · strength 0.30
  25. Patrick Michl · 4 shared papers, 2013–2021 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.